NASDAQ$GOSS
Gossamer Bio Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Announced third quarter 2021 financial results and provided a corporate update.
Gossamer Bio reported a net loss of $60.2 million for the third quarter of 2021, with cash, cash equivalents, and marketable securities totaling $366 million as of September 30, 2021.
- Topline results from the Phase 2 TORREY study of Seralutinib in PAH patients are now expected in the second half of 2022 due to COVID-19-related delays.
- Enrollment has been completed for the Phase 2 SHIFT-UC study of GB004 in UC patients, with 12-week topline results expected in the second quarter of 2022.
- GB5121, a covalent, CNS-penetrant BTK inhibitor for PCNSL, has advanced into a Phase 1 trial in healthy volunteers.
- As of September 30, 2021, the company's cash, cash equivalents, and marketable securities totaled $366 million.
Headline financials
Revenue & EPS history
Gossamer Bio · Revenue · Quarterly
$0
Revenue by segment
Gossamer Bio · $17M total across 1 segment · Q1 2026
- Collaborators$17M—100.0%
Forward guidance
Gossamer Bio anticipates several key milestones and activities in the near term.
Tailwinds
- Advancement of GB5121 into a Phase 1 trial.
- Initiation of a Phase 1b/2 clinical trial of GB5121 in PCSNL patients in the first half of 2022.
- Initiation of a first-in-human Phase 1 clinical trial of GB7208 in healthy volunteers in the second half of 2022.
- Funding its operating and capital expenditures into the second half of 2023.
- 12-week topline data from the SHIFT-UC study are expected in the second quarter of 2022.
Headwinds
- Potential delays in the commencement, enrollment and completion of clinical trials
- Disruption to our operations from the ongoing global outbreak of the COVID-19 pandemic, including clinical trial delays and clinical site staff shortages
- Dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing
- Unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development
- May use its capital resources sooner than it expects
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
13 / 30 earnings
Positive
+15.2%
Q4 2022
Best reaction
-15.6%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -34.9% | -50.9% | |
| Q4 2025 | -10.8% | -21.0% | -5.5% | |
| Q3 2025 | +2.2% | +16.9% | +44.2% | |
| Q2 2025 | -8.5% | -18.9% | +15.7% | |
| Q1 2025 | +1.0% | +9.5% | +18.1% | |
| Q4 2024 | +0.0% | +6.0% | -38.4% | |
| Q3 2024 | -0.9% | -4.4% | -15.1% | |
| Q2 2024 | +4.3% | +7.5% | +12.5% | |
| Q1 2024 | -3.2% | -5.0% | -23.2% | |
| Q4 2023 | +4.1% | -4.8% | -26.2% | |
| Q3 2023 | -12.0% | +4.7% | +73.1% | |
| Q2 2023 | -7.0% | -9.3% | -24.7% | |
| Q1 2023 | +3.7% | -11.8% | -7.4% | |
| Q4 2022 | +15.2% | +5.7% | -0.5% | |
| Q3 2022 | -0.8% | -4.2% | -14.9% | |
| Q2 2022 | +4.6% | +6.5% | +13.7% | |
| Q1 2022 | +12.5% | +34.2% | +9.5% | |
| Q4 2021 | +3.7% | +1.0% | -2.8% | |
| Q3 2021 | -1.4% | -9.1% | -16.6% | |
| Q2 2021 | -0.8% | +9.5% | +18.9% | |
| Q1 2021 | -0.7% | -0.7% | +1.7% | |
| Q4 2020 | -9.4% | -5.5% | -11.6% | |
| Q3 2020 | -0.9% | -1.3% | +4.2% | |
| Q2 2020 | +5.1% | +2.4% | -1.1% | |
| Q1 2020 | -15.6% | -11.5% | -27.8% | |
| Q4 2019 | +5.5% | +5.7% | +40.0% | |
| Q3 2019 | -4.3% | -1.2% | +12.4% | |
| Q2 2019 | -2.5% | +3.2% | +2.6% | |
| Q1 2019 | +1.3% | +3.7% | -3.9% | |
| Q4 2018 | -4.9% | -10.8% | -30.1% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro